Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 6, 2021-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January
View HTML
Toggle Summary Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
WHIPPANY, N.J. & SAN FRANCISCO --(BUSINESS WIRE)--Dec. 22, 2020-- Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression
View HTML
Toggle Summary Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 21, 2020-- Veracyte , Inc. (Nasdaq: VCYT) today announced that the company has received ISO 13485:2016 certification for its Quality Management System (QMS) for the design, development and manufacture of genomic in vitro diagnostic (IVD) tests
View HTML
Toggle Summary Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
Data on Noninvasive Nasal Swab Test and Percepta Genomic Atlas Presented Today at Virtual Lung Cancer R&D Day SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 16, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced new preliminary performance data for its noninvasive nasal swab test for early lung
View HTML
Toggle Summary Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 15, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer
View HTML
Toggle Summary Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 3, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&D Day for investors and analysts on December 16, 2020 , from 10:00 a.m. to 12:00 p.m. EST .
View HTML
Toggle Summary Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson , chairman and chief executive officer, will participate in a fireside chat and host one-on-one meetings at the Piper Sandler
View HTML
Toggle Summary Veracyte Announces New General Manager Structure to Advance Global Expansion
John Hanna appointed GM , endocrinology, breast cancer and lymphoma; Morten Frost to join company as GM , pulmonology SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 17, 2020-- Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company’s growing roster
View HTML
Toggle Summary Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a pioneering genomic diagnostics company, announced that the Federal Joint Committee (G-BA) has approved its Prosigna® Breast Cancer Gene Signature Assay. The G-BA decision to reimburse the Prosigna test
View HTML
Toggle Summary Veracyte Announces Third Quarter 2020 Financial Results
Revenue of $31.1 Million ; Product and Testing Revenue Increased 79% Over Second Quarter of 2020 Achieved Key Reimbursement Milestones Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2020-- Veracyte, Inc .
View HTML